Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.


TSXV:SBM - Post by User

Comment by Pandoraon Sep 29, 2022 12:54pm
92 Views
Post# 34995226

RE:RE:RE:RE:RE:total ballpark deal value

RE:RE:RE:RE:RE:total ballpark deal value
biorun wrote: Engcan77 - sorry, I was only looking at the middle and back end of the deal.

Whether the upfront is 1 million, 2 million, or even 5 million, that really doesn't do anything to move the share price or affect the overall deal value. Its really the total value of the agreement over the term which evidently looked at Abbvie's own forecasts as the key reference point. 

If they shared those forecasts with us, I am sure we would feel so much better, but again, we meander in the dark and have to try to guestimate the most likely scenario with the data clues they have clearly provided in the presentation deck. The presentation clearly said that the upfront was sacrificed for sustained revenue in future in the form of a better long term royalty so I discounted that in the back of the envelope analysis.

The company sees the deal as "amazing", but its not so "amazing" for us having seen over 110% of our increased valuation wiped off the table since the deal was announced (from 35c).

You know when everything was put on the table, I am sure they looked at all the variants of how the deal would play out, and decided on a longer term revenue stream over whatever upfront payments could be negotiated. In the end, if Linda was ok with the deal, as it has been read, then I guess that the fruit was fully squeezed and that is the very best we could ask for.

CEOs must always balance the long term interests of the company with the short term expecations of shareholders which is reflected in the appreciation of the market share price. I need say no more.

In my view, they can immediately appoint Bieber to the post as interim CEO while they complete the placement for a longer term appointee. If you do a little dd on him (both on the internet and otherwise), one would find that he is highly effective, extraordinarly well connected and is a door opener with like minded top executives in the big pharma space.  The fact that he has both the scientific and executive background to make such overall conclusions about Geraldine's science is extraordinarily valuable to my confidence in the longer term future.

All I can say is today is that I am 110% with Geraldine here and so grateful for her outstanding leadership contribution. The product is all there to make the company hundreds of millions or more, this company deperately needs a leader who will invest in Sirona and take it there.

Geraldine and her scientific team are really the Saints of Sirona.


If the company is guaranteed 17 years of "Royalty" payments how would it be if they guaranteed shareholders 17 years of a dividend payment -- say at 5% or so? Would that also provide a boost to the shareprice?

I thought they might at least regurgitate the news release at the open this morning but they couldn't even be bothered to do that. You can measure just how much they are concerned about "shareholder value". Today's share price is a good indication.
<< Previous
Bullboard Posts
Next >>